The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications

Neuromuscular Disorders

Volumn 24, Issue 11, 2014, Pages 943-952

  Moran, Ellen M ^a   Mastaglia, Frank L ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Dermatomyositis; IL 17A; Inclusion body myositis; Inflammatory myopathies; Polymyositis; Th17

Indexed keywords

AUTOANTIBODY; BRODALUMAB; CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 17; IXEKIZUMAB; SECUKINUMAB; TOCILIZUMAB;

AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; MYOSITIS; NONHUMAN; POLYMYOSITIS; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; IMMUNOLOGY; METABOLISM; MYELITIS; PHYSIOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-17; MYELITIS; TH17 CELLS;

EID: 84922283781     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.06.432     Document Type: Review

References (128)

1. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012, 11:203-206.
2. Dalakas M.C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006, 2:219-227.
3. Greenberg S.A. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007, 19:536-541.
4. Zong M., Lundberg I.E. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011, 7:297-306.
5. Loell I., Lundberg I.E. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?. J Intern Med 2011, 269:243-257.
6. Kissel J.T., Halterman R.K., Rammohan K.W., Mendell J.R. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26-30.
7. Kissel J.T., Mendell J.R., Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329-334.
8. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986, 19:112-125.
9. + suppressor cells. Ann Neurol 1988, 23:493-499.
10. Goebels N., Michaelis D., Engelhardt M., et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996, 97:2905-2910.
11. Fasth A.E., Dastmalchi M., Rahbar A., et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009, 183:4792-4799.
12. Askanas V., Engel W.K., Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012, 71:680-693.
13. Cappelletti C., Baggi F., Zolezzi F., et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011, 76:2079-2088.
14. Preusse C., Goebel H.H., Held J., et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012, 181:2161-2171.
15. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988, 23:168-173.
16. Behrens L., Kerschensteiner M., Misgeld T., Goebels N., Wekerle H., Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998, 161:5943-5951.
17. Murata K., Dalakas M.C. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999, 155:453-460.
18. Wiendl H., Mitsdoerffer M., Schneider D., et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003, 126:1026-1035.
19. + T cell cytotoxicity. Brain 2004, 127:1182-1190.
20. Goebels N., Michaelis D., Wekerle H., Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992, 149:661-667.
21. Wiendl H., Lautwein A., Mitsdorffer M., et al. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol 2003, 138:132-143.
22. De Visser M., Emslie-Smith A.M., Engel A.G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989, 94:181-192.
23. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
24. Gitiaux C., Kostallari E., Lafuste P., Authier F.J., Christov C., Gherardi R.K. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis 2013, 72:445-452.
25. Dalakas M., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
26. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
27. Salajegheh M., Kong S.W., Pinkus J.L., et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010, 67:53-63.
28. Englund P., Nennesmo I., Klareskog L., Lundberg I.E. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002, 46:1044-1055.
29. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Ronnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
30. Love L.A., Leff R.L., Fraser D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
31. Casciola-Rosen L., Mammen A.L. Myositis autoantibodies. Curr Opin Rheumatol 2012, 24:602-608.
32. Mohassel P., Mammen A.L. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013, 48:477-483.
33. Larman H.B., Salajegheh M., Nazareno R., et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013, 73:408-418.
34. Pluk H., van Hoeve B.J., van Dooren S.H., et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013, 73:397-407.
35. Mathews M.B., Bernstein R.M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983, 304:177-179.
36. Hengstman G.J., Brouwer R., Egberts W.T., et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002, 249:69-75.
37. Hengstman G.J., van Brenk L., Vree Egberts W.T. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005, 252:534-537.
38. Gunawardena H., Betteridge Z.E., McHugh N.J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009, 48:607-612.
39. Targoff I.N., Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985, 28:796-803.
40. Robinson A.B., Reed A.M. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011, 7:664-675.
41. Rider L.G., Lachenbruch P.A., Monroe J.B., et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425-3435.
42. Stone K.B., Oddis C.V., Fertig N., et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007, 56:3125-3131.
43. Casciola-Rosen L., Nagaraju K., Plotz P., et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201:591-601.
44. Mammen A.L., Casciola-Rosen L.A., Hall J.C., Christopher-Stine L., Corse A.M., Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009, 60:3784-3793.
45. Tournadre A., Miossec P. A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol 2013, 9:438-442.
46. Howard O.M., Dong H.F., Yang D., et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002, 196:781-791.
47. Figarella-Branger D., Civatte M., Bartoli C., Pellissier J.F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003, 28:659-682.
48. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., Schroder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
49. Raju R., Vasconcelos O., Granger R., Dalakas M.C. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003, 141:125-131.
50. Carstens P.O., Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014, 175:349-358.
51. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005, 26:373-380.
52. Rayavarapu S., Coley W., Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol 2011, 23:579-584.
53. Greenberg S.A. DNA microarray gene expression analysis technology and its application to neurological disorders. Neurology 2001, 57:755-761.
54. Raju R., Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005, 128:1887-1896.
55. + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154-4163.
56. Choi Y.C., Dalakas M.C. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000, 54:65-71.
57. Walsh R.J., Kong S.W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792.
58. Wenzel J., Scheler M., Bieber T., Tuting T. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br J Dermatol 2005, 153:462-463. [author reply 3-4].
59. Ivanidze J., Hoffmann R., Lochmuller H., Engel A.G., Hohlfeld R., Dornmair K. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011, 179:1347-1359.
60. Baeten D.L., Kuchroo V.K. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med 2013, 19:824-825.
61. Moran E.M., Heydrich R., Ng C.T., et al. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 2011, 6:e24048.
62. Kenna T.J., Brown M.A. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 2013, 9:375-379.
63. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 2007, 56:2111-2115.
64. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
65. Yao Z., Painter S.L., Fanslow W.C., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
66. Fossiez F., Djossou O., Chomarat P., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
67. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776.
68. Aarvak T., Chabaud M., Miossec P., Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
69. Chabaud M., Aarvak T., Garnero P., Natvig J.B., Miossec P. Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions. Cytokine 2001, 13:113-118.
70. Infante-Duarte C., Horton H.F., Byrne M.C., Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107-6115.
71. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
72. Happel K.I., Zheng M., Young E., et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003, 170:4432-4436.
73. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
74. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
75. Park H., Li Z., Yang X.O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
76. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
77. Langrish C.L., Chen Y., Blumenschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
78. + T-cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014, 66:1272-1281.
79. Huber M., Heink S., Grothe H., et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol 2009, 39:1716-1725.
80. Skepner J., Ramesh R., Trocha M., et al. Pharmacologic inhibition of RORgammat regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol 2014, 192(6):2564-2575.
81. Abe M., Hiasa Y., Onji M. T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol 2013, 2013:607073.
82. Chen X., Oppenheim J.J. Th17 cells and Tregs: unlikely allies. J Leukoc Biol 2014, 95:723-731.
83. Moran E.M., Connolly M., Gao W., McCormick J., Fearon U., Veale D.J. Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis Rheum 2011, 63:3263-3273.
84. Moran E.M., Mullan R., McCormick J., et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 2009, 11:R113.
85. Xu S., Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol 2010, 7:164-174.
86. Mountz J.D., Wang J.H., Xie S., Hsu H.C. Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease. Discov Med 2011, 11:76-85.
87. Wang J.H., New J.S., Xie S., et al. Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice. Arthritis Rheum 2013, 65:2703-2712.
88. Xie S., Li J., Wang J.H., et al. IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J Immunol 2010, 184:2289-2296.
89. Doreau A., Belot A., Bastid J., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
90. Lin Y., Ritchea S., Logar A., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31:799-810.
91. O'Connor W., Kamanaka M., Booth C.J., et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009, 10:603-609.
92. Chevrel G., Page G., Granet C., Streichenberger N., Varennes A., Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003, 137:125-133.
93. Page G., Chevrel G., Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208.
94. Tournadre A., Porcherot M., Cherin P., Marie I., Hachulla E., Miossec P. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009, 46:297-301.
95. Kim G.T., Cho M.L., Park Y.E., et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2010, 29:273-279.
96. Brunn A., Zornbach K., Hans V.H., Haupt W.F., Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 2012, 71:855-867.
97. Ciccia F., Rizzo A., Alessandro R., et al. Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. Rheumatology (Oxford) 2014, 53(7):1307-1312.
98. Higgs B.W., Zhu W., Richman L., et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012, 15:25-35.
99. Szodoray P., Alex P., Knowlton N., et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 2010, 49:1867-1877.
100. Hatice Bilgic SRY, McNallan Kelly T, Wilson Joseph C, Koeuth T, Bauer Jason W, Moder Kevin G, Amin Shreyasee, Michet Clement J, Peterson Erik J, Baechler Emily C, Reed Ann M. Abstract # 2053 IL-17 and IFN-regulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. In: American College of Rheumatology (ACR). San Francisco; 2008.
101. Oddis C.V., Reed A.M., Aggarwal R., et al. Cell depletion in refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - the RIM (rituximab in myositis) trial. Arthritis Rheum 2013, 65:S877-S878.
102. Lopez de Padilla C., Crowson C.S., Hein M.S., et al. Interferon-regulated chemokine and innate cytokine scores identify refractory myositis patients that respond better to rituximab therapy. Arthritis Rheum 2013, 65:S887-S888. 10.1002/art.38216: 10.1002/art.38216.
103. Shen H., Xia L., Lu J., Xiao W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011, 40:217-220.
104. Allenbach Y., Chaara W., Rosenzwajg M., et al. Th1 response and systemic Treg deficiency in inclusion body myositis. PLoS One 2014, 9:e88788.
105. Tang X., Tian X., Zhang Y., et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol 2013, 2013:345347-345354.
106. Chevrel G., Granet C., Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005, 64:1257-1262.
107. Kocic J., Santibanez J.F., Krstic A., et al. Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2. Biochim Biophys Acta 2012, 1823:838-849.
108. Kocic J., Santibanez J.F., Krstic A., Mojsilovic S., Ilic V., Bugarski D. Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase. Int J Biochem Cell Biol 2013, 45:464-475.
109. Zong M., Dorph C., Dastmalchi M., et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2013, 73:913-920.
110. Reed A.M., Crowson C.S., Hein M.S., et al. Biomarker and serologic predictors of clinical improvement after B Cell depletion in refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - the RIM (rituximab in myositis) trial. Arthritis Rheum 2013, 65:S877-S878. 10.1002/art.38216: 10.1002/art.38216.
111. Amemiya K., Semino-Mora C., Granger R.P., Dalakas M.C. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000, 94:99-104.
112. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994, 94:1729-1735.
113. Dalakas M.C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998, 51:S37-S45.
114. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
115. + T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010, 225:137-142.
116. Antiga E., Kretz C.C., Klembt R., et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 2010, 35:342-350.
117. Allenbach Y., Rosenzwajg M., Prevel N., et al. P5.27 evidence for the implication of Th-1 and Treg cells but not Th-17 in sporadic inclusion body myositis. NMD 2011, 21:732.
118. Keijzer C., van der Zee R., van Eden W., Broere F. Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases. Front Immunol 2013, 4:245.
119. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
120. Venalis P., Lundberg I.E. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) 2014, 53:397-405.
121. Lundberg I., Ulfgren A.K., Nyberg P., Andersson U., Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874.
122. Lepidi H., Frances V., Figarella-Branger D., Bartoli C., Machado-Baeta A., Pellissier J.F. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998, 24:73-79.
123. Gabay C., Gay-Croisier F., Roux-Lombard P., et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994, 37:1744-1751.
124. Narazaki M., Hagihara K., Shima Y., Ogata A., Kishimoto T., Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 2011, 50:1344-1346.
125. + T helper cells. Cell 2006, 126:1121-1133.
126. Huh J.R., Littman D.R. Small molecule inhibitors of RORgammat: targeting Th17 cells and other applications. Eur J Immunol 2012, 42:2232-2237.
127. Williams S.C. Flurry of deal-making surrounds new autoimmunity target. Nat Med 2013, 19:1078.
128. Tse M.T. IL-17 antibodies gain momentum. Nat Rev Drug Discov 2013, 12:815-816.